BidaskClub lowered shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) from a sell rating to a strong sell rating in a research report report published on Tuesday.

PETX has been the subject of several other research reports. Jefferies Group LLC set a $8.00 price objective on Aratana Therapeutics and gave the company a buy rating in a research note on Thursday, June 8th. Zacks Investment Research raised Aratana Therapeutics from a hold rating to a buy rating and set a $8.00 price objective for the company in a research note on Tuesday, July 4th. Stifel Nicolaus lowered their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a buy rating for the company in a research note on Wednesday, May 10th. Finally, ValuEngine downgraded Aratana Therapeutics from a hold rating to a sell rating in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $9.50.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded down 2.38% during midday trading on Tuesday, hitting $5.74. 456,210 shares of the company were exchanged. Aratana Therapeutics has a one year low of $4.97 and a one year high of $10.73. The company’s market capitalization is $246.83 million. The company has a 50-day moving average of $6.98 and a 200 day moving average of $6.41.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The company had revenue of $5.16 million during the quarter, compared to the consensus estimate of $4.50 million. During the same quarter in the prior year, the firm posted $0.61 earnings per share. The firm’s revenue was down 86.4% compared to the same quarter last year. On average, equities research analysts expect that Aratana Therapeutics will post ($1.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://theolympiareport.com/2017/08/12/aratana-therapeutics-inc-petx-lowered-to-strong-sell-at-bidaskclub.html.

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Aratana Therapeutics by 4.5% in the first quarter. Geode Capital Management LLC now owns 243,352 shares of the biopharmaceutical company’s stock valued at $1,289,000 after buying an additional 10,465 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock valued at $10,211,000 after buying an additional 235,208 shares during the last quarter. Financial Counselors Inc. bought a new stake in shares of Aratana Therapeutics during the first quarter valued at approximately $101,000. Cadence Capital Management LLC boosted its stake in shares of Aratana Therapeutics by 21.7% in the first quarter. Cadence Capital Management LLC now owns 131,926 shares of the biopharmaceutical company’s stock valued at $699,000 after buying an additional 23,506 shares during the last quarter. Finally, American International Group Inc. boosted its stake in shares of Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the last quarter. Institutional investors and hedge funds own 67.85% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.